Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases | Zendy

Ute Oltmanns | Zendy; Nicolas Kahn | Zendy; Karin Palmowski | Zendy; Annette Träger | Zendy; Heinrich Wenz | Zendy; Claus Peter Heußel | Zendy; Philipp A. Schnabel | Zendy; Michael Puderbach | Zendy; M Wiebel | Zendy; Svenja Ehlers-Tenenbaum | Zendy; Arne Warth | Zendy; Felix J.F. Herth | Zendy; Michael Kreuter | Zendy

Open Access

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases

Author(s) -

Ute Oltmanns,

Nicolas Kahn,

Karin Palmowski,

Annette Träger,

Heinrich Wenz,

Claus Peter Heußel,

Philipp A. Schnabel,

Michael Puderbach,

M Wiebel,

Svenja Ehlers-Tenenbaum,

Arne Warth,

Felix J.F. Herth,

Michael Kreuter

Publication year - 2014

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000363064

Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , adverse effect , discontinuation , interstitial lung disease , pulmonary function testing , dlco , vital capacity , pulmonary fibrosis , gastroenterology , surgery , fibrosis , lung , lung function , diffusing capacity

Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). However, adverse events may offset treatment benefits and compliance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research